Free access

Research article

First published online October 1, 2016

Racial and Ethnic Differences in the Epidemiology and Genomics of Lung Cancer

Matthew B. Schabath, Phd [email protected], W. Douglas Cress, Phd, and Teresita Muñoz-Antonia, PhdView all authors and affiliations

https://doi.org/10.1177/107327481602300405

Abstract

Background

Lung cancer is the most common cancer in the world. In addition to the geographical and sex-specific differences in the incidence, mortality, and survival rates of lung cancer, growing evidence suggests that racial and ethnic differences exist.

Methods

We reviewed published data related to racial and ethnic differences in lung cancer.

Results

Current knowledge and substantive findings related to racial and ethnic differences in lung cancer were summarized, focusing on incidence, mortality, survival, cigarette smoking, prevention and early detection, and genomics. Systems-level and health care professional–related issues likely to contribute to specific racial and ethnic health disparities were also reviewed to provide possible suggestions for future strategies to reduce the disproportionate burden of lung cancer.

Conclusions

Although lung carcinogenesis is a multifactorial process driven by exogenous exposures, genetic variations, and an accumulation of somatic genetic events, it appears to have racial and ethnic differences that in turn impact the observed epidemiological differences in rates of incidence, mortality, and survival.

References

1. American Cancer Society. Global Cancer Facts & Figures. 3rd ed. http://www.cancer.org/acs/groups/content/@research/documents/document/acspc-044738.pdf. Accessed September 1, 2016.

2. International Agency for Research on Cancer; World Health Organization. GLOBOCAN 2012: estimated cancer incidence, mortality and prevalence worldwide in 2012. http://globocan.iarc.fr/Pages/fact_sheets_cancer.aspx. Accessed August 29, 2016.

3. American Cancer Society. Cancer Facts & Figures 2016. http://www.cancer.org/acs/groups/content/@research/documents/document/acspc-047079.pdf. Accessed August 29, 2016.

4. Farjah F., Wood D.E., Yanez N.D. 3rdet al. Racial disparities among patients with lung cancer who were recommended operative therapy. Arch Surg. 2009; 144(1): 14–18.

5. Steele C.B., Pisu M., Richardson L.C. Urban/rural patterns in receipt of treatment for non-small cell lung cancer among black and white Medicare beneficiaries, 2000-2003. J Natl Med Assoc. 2011; 103(8): 711–718.

6. Esnaola N.F., Gebregziabher M., Knott K.et al. Underuse of surgical resection for localized, non-small cell lung cancer among whites and African Americans in South Carolina. Ann Thorac Surg. 2008; 86(1): 220–226.

7. van Ryn M. Research on the provider contribution to race/ethnicity disparities in medical care. Med Care. 2002; 40(1 suppl): I140–I151.

8. Underwood J.M., Townsend J.S., Tai E.et al. Racial and regional disparities in lung cancer incidence. Cancer. 2012; 118(7): 1910–1918.

9. Yang R., Cheung M.C., Byrne M.M.et al. Do racial or socioeconomic disparities exist in lung cancer treatment? Cancer. 2010; 116(10): 2437–2447.

10. Howlader N., Noone A.M., Krapcho M., eds. SEER Cancer Statistics Review, 1975-2012. Bethesda, MD: National Cancer Institute. Based on November 2014 SEER data submission, posted to the SEER web site, April 2015. http://seer.cancer.gov/csr/1975_2012. Accessed June 30, 2016.

11. Centers for Disease Control and Prevention. Racial/ethnic disparities and geographic differences in lung cancer incidence: 38 states and the District of Columbia, 1998-2006. MMWR Morb Mortal Wkly Rep. 2010; 59(44): 1434–1438.

12. Sankar P., Cho M.K. Genetics. Toward a new vocabulary of human genetic variation. Science. 2002; 298(5597): 1337–1338.

13. Witzig R. The medicalization of race: scientific legitimization of a flawed social construct. Ann Intern Med. 1996; 125(8): 675–679.

14. Grieco E.M., Cassidy R.C. Overview of race and Hispanic origin. Census 2000 brief. https://www.census.gov/prod/2001pubs/c2kbr01-1.pdf. Accessed August 29, 2016.

15. Islami F., Torre L.A., Jemal A. Global trends of lung cancer mortality and smoking prevalence. Transl Lung Cancer Res. 2015; 4(4): 327–338.

16. Harris K., Khachaturova I., Azab B.et al. Small cell lung cancer doubling time and its effect on clinical presentation: a concise review. Clin Med Insights Oncol. 2012; 6: 199–203.

17. Schabath M.B., Thompson Z.J., Gray J.E. Temporal trends in demographics and overall survival of non-small-cell lung cancer patients at Moffitt Cancer Center from 1986 to 2008. Cancer Control. 2014; 21(1): 51–56.

18. Kachroo S., Tong L., Spitz M.R.et al. Trends in prevalence of prognostic factors and survival in lung cancer patients from 1985 to 2004 at a tertiary care center. Cancer Detect Prev. 2008; 32(2): 101–108.

19. Dela Cruz C.S., Tanoue L.T., Matthay R.A. Lung cancer: epidemiology, etiology, and prevention. Clin Chest Med. 2011; 32(4): 605–644.

20. Birim O., Kappetein A.P., van Klaveren R.J.et al. Prognostic factors in non-small cell lung cancer surgery. Eur J Surg Oncol. 2006; 32(1): 12–23.

21. National Cancer Institute. SEER Survival Monograph: Cancer Survival Among Adults: U.S. SEER Program, 1988-2001, Patient and Tumor Characteristics. NIH pub. no. 076215, 2007. https://surveillance.cancer.gov/publications/factsheets/SEER_Cancer_Survivor_Fact_Sheet.pdf. Accessed August 29, 2016.

22. Paesmans M., Sculier J.P., Lecomte J.et al. Prognostic factors for patients with small cell lung carcinoma: analysis of a series of 763 patients included in 4 consecutive prospective trials with a minimum follow-up of 5 years. Cancer. 2000; 89(3): 523–533.

23. Spiegelman D., Maurer L.H., Ware J.H.et al. Prognostic factors in small-cell carcinoma of the lung: an analysis of 1,521 patients. J Clin Oncol. 1989; 7(3): 344–354.

24. Albain K.S., Crowley J.J., LeBlanc M.et al. Determinants of improved outcome in small-cell lung cancer: an analysis of the 2,580-patient Southwest Oncology Group data base. J Clin Oncol. 1990; 8(9): 1563–1574.

25. Osterlind K., Andersen P.K. Prognostic factors in small cell lung cancer: multivariate model based on 778 patients treated with chemotherapy with or without irradiation. Cancer Res. 1986; 46(8): 4189–4194.

26. Schabath M.B., Nguyen A., Wilson P.et al. Temporal trends from 1986 to 2008 in overall survival of small cell lung cancer patients. Lung Cancer. 2014; 86(1): 14–21.

27. Santarpia M., Giovannetti E., Rolfo C.et al. Recent developments in the use of immunotherapy in non-small cell lung cancer. Expert Rev Respir Med. 2016; 10(7): 781–798.

28. Tchekmedyian N., Gray J.E., Creelan B.C.et al. Propelling immunotherapy combinations into the clinic. Oncology (Williston Park). 2015; 29(12): pii: 214814.

29. Brahmer J.R. Harnessing the immune system for the treatment of non-small-cell lung cancer. J Clin Oncol. 2013; 31(8): 1021–1028.

30. Margolis M.L., Christie J.D., Silvestri G.A.et al. Racial differences pertaining to a belief about lung cancer surgery: results of a multicenter survey. Ann Intern Med. 2003; 139(7): 558–563.

31. Shugarman L.R., Mack K., Sorbero M.E.et al. Race and sex differences in the receipt of timely and appropriate lung cancer treatment. Med Care. 2009; 47(7): 774–781.

32. Zullig L.L., Carpenter W.R., Provenzale D.T.et al. The association of race with timeliness of care and survival among Veterans Affairs health care system patients with late-stage non-small cell lung cancer. Cancer Manag Res. 2013; 5: 157–163.

33. Howington J.A., Blum M.G., Chang A.C.et al. Treatment of stage I and II non-small cell lung cancer: diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2013; 143(5 suppl): e278S–e313S.

34. Lin J.J., Mhango G., Wall M.M.et al. Cultural factors associated with racial disparities in lung cancer care. Ann Am Thorac Soc. 2014; 11(4): 489–495.

35. Hardy D., Liu C.C., Xia R.et al. Racial disparities and treatment trends in a large cohort of elderly black and white patients with non-small cell lung cancer. Cancer. 2009; 115(10): 2199–2211.

36. Hardy D., Xia R., Liu C.C.et al. Racial disparities and survival for non-small-cell lung cancer in a large cohort of black and white elderly patients. Cancer. 2009; 115(20): 4807–4818.

37. US Department of Health and Human Services. The Health Consequences of Smoking: 50 Years Of Progress. A Report of the Surgeon General. Atlanta, GA: US Department of Health and Human Services; Centers for Disease Control and Prevention; National Center for Chronic Disease Prevention and Health Promotion; Office on Smoking and Health; 2014.

38. Carter B.D., Freedman N.D., Jacobs E.J. Smoking and mortality: beyond established causes. N Engl J Med. 2015; 372(22): 2170.

39. Pesch B., Kendzia B., Gustavsson P.et al. Cigarette smoking and lung cancer: relative risk estimates for the major histological types from a pooled analysis of case-control studies. Int J Cancer. 2012; 131(5): 1210–1219.

40. US Department of Health and Human Services. How Tobacco Smoke Causes Disease: The Biology and Behavioral Basis for Smoking-Attributable Disease: A Report of the Surgeon General. Atlanta: US Department of Health and Human Services; Centers for Disease Control and Prevention; National Center for Chronic Disease Prevention and Health Promotion; Office on Smoking and Health; 2010.

41. Jamal A., Homa D.M., O'Connor E.et al. Current cigarette smoking among adults: United States, 2005-2014. MMWR Morb Mortal Wkly Rep. 2015; 64(44): 1233–1240.

42. Centers for Disease Control and Prevention. Cigarette smoking among adults: United States, 2006. MMWR Morb Mortal Wkly Rep. 2007; 56(44): 1157–1161.

43. Jamal A., Agaku I.T., O'Connor E.et al. Current cigarette smoking among adults: United States, 2005-2013. MMWR Morb Mortal Wkly Rep. 2014; 63(47): 1108–1112.

44. Haiman C.A., Stram D.O., Wilkens L.R.et al. Ethnic and racial differences in the smoking-related risk of lung cancer. N Engl J Med. 2006; 354(4): 333–342.

45. Driscoll T., Nelson D.I., Steenland K.et al. The global burden of disease due to occupational carcinogens. Am J Ind Med. 2005; 48(6): 419–431.

46. Alberg A.J., Brock M.V., Ford J.G.et al. Epidemiology of lung cancer: diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2013; 143(5 suppl): e1S–e29S.

47. Brinton L.A., Gierach G.L., Andaya A.et al. Reproductive and hormonal factors and lung cancer risk in the NIH-AARP Diet and Health Study cohort. Cancer Epidemiol Biomarkers Prev. 2011; 20(5): 900–911.

48. Yao Y., Gu X., Zhu J.et al. Hormone replacement therapy in females can decrease the risk of lung cancer: a meta-analysis. PLoS One. 2013; 8(8): e71236.

49. Yang Y., Dong J., Sun K.et al. Obesity and incidence of lung cancer: a meta-analysis. Int J Cancer. 2013; 132(5): 1162–1169.

50. Smith L., Brinton L.A., Spitz M.R.et al. Body mass index and risk of lung cancer among never, former, and current smokers. J Natl Cancer Inst. 2012; 104(10): 778–789.

51. Wu S.H., Liu Z. Soy food consumption and lung cancer risk: a meta-analysis using a common measure across studies. Nutr Cancer. 2013; 65(5): 625–632.

52. Wu Q.J., Xie L., Zheng W.et al. Cruciferous vegetables consumption and the risk of female lung cancer: a prospective study and a metaanalysis. Ann Oncol. 2013; 24(7): 1918–1924.

53. Song J., Su H., Wang B.L.et al. Fish consumption and lung cancer risk: systematic review and meta-analysis. Nutr Cancer. 2014; 66(4): 539–549.

54. Aberle D.R., Adams A.M., Berg C.D.et al. Reduced lung-cancer mortality with low-dose computed tomographic screening. N Engl J Med. 2011; 365(5): 395–409.

55. Slatore C.G., Baumann C., Pappas M.et al. Smoking behaviors among patients receiving computed tomography for lung cancer screening. Systematic review in support of the U.S. Preventive Services Task Force. Ann Am Thorac Soc. 2014; 11(4): 619–627.

56. US Preventive Services Task Force. Lung cancer: screening, December 2013. http://www.uspreventiveservicestaskforce.org/Page/Document/RecommendationStatementFinal/lung-cancer-screening. Accessed August 29, 2016.

57. Tanner N.T., Gebregziabher M., Hughes Halbert C.et al. Racial differences in outcomes within the National Lung Screening Trial. Implications for widespread implementation. Am J Respir Crit Care Med. 2015; 192(2): 200–208.

58. Kumar P., Gareen I.F., Lathan C.et al. Racial differences in tobacco cessation and treatment usage after lung screening: an examination of the National Lung Screening Trial. Oncologist. 2016; 21(1): 40–49.

59. Pinsky P.F., Zhu C.S., Kramer B.S. Lung cancer risk by years since quitting in 30+ pack year smokers. J Med Screen. 2015; 22(3): 151–157.

60. Clinical Lung Cancer Genome Project (CLCGP); Network Genomic Medicine (NGM). A genomics-based classification of human lung tumors. Sci Transl Med. 2013; 5(209): 209ra153.

61. Pao W., Girard N. New driver mutations in non-small-cell lung cancer. Lancet Oncol. 2011; 12(2): 175–180.

62. Cress W.D., Chiappori A., Santiago P.et al. Lung cancer mutations and use of targeted agents in Hispanics. Rev Recent Clin Trials. 2014; 9(4): 225–232.

63. Politi K., Herbst R.S. Lung cancer in the era of precision medicine. Clin Cancer Res. 2015; 21(10): 2213–2220.

64. Bollig-Fischer A., Chen W., Gadgeel S.M.et al. Racial diversity of actionable mutations in non-small cell lung cancer. J Thorac Oncol. 2015; 10(2): 250–255.

65. Zhou W., Christiani D.C. East meets West: ethnic differences in epidemiology and clinical behaviors of lung cancer between East Asians and Caucasians. Chin J Cancer. 2011; 30(5): 287–292.

66. da Cunha Santos G., Shepherd F.A.et al. EGFR mutations and lung cancer. Annu Rev Pathol. 2011; 6: 49–69.

67. Pao W., Miller V., Zakowski M.et al. EGF receptor gene mutations are common in lung cancers from “never smokers” and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci U S A. 2004; 101(36): 13306–13311.

68. Paez J.G., Janne P.A., Lee J.C.et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science. 2004; 304(5676): 1497–1500.

69. Soh J., Okumura N., Lockwood W.W.et al. Oncogene mutations, copy number gains and mutant allele specific imbalance (MASI) frequently occur together in tumor cells. PLoS One. 2009; 4(10): e7464.

70. Ladanyi M., Pao W. Lung adenocarcinoma: guiding EGFR-targeted therapy and beyond. Mod Pathol. 2008; 21(suppl 2): S16–S22.

71. Shi Y., Li J., Zhang S.et al. Molecular epidemiology of EGFR mutations in Asian patients with advanced non-small-cell lung cancer of adenocarcinoma histology - mainland China subset analysis of the PIONEER study. PLoS One. 2015; 10(11): e0143515.

72. Dogan S., Shen R., Ang D.C.et al. Molecular epidemiology of EGFR and KRAS mutations in 3,026 lung adenocarcinomas: higher susceptibility of women to smoking-related KRAS-mutant cancers. Clin Cancer Res. 2012; 18(22): 6169–6177.

73. Varghese A.M., Sima C.S., Chaft J.E.et al. Lungs don't forget: comparison of the KRAS and EGFR mutation profile and survival of collegiate smokers and never smokers with advanced lung cancers. J Thorac Oncol. 2013; 8(1): 123–125.

74. Shigematsu H., Lin L., Takahashi T.et al. Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers. J Natl Cancer Inst. 2005; 97(5): 339–346.

75. Yang J.C., Wu Y.L., Chan V.et al. Epidermal growth factor receptor mutation analysis in previously unanalyzed histology samples and cytology samples from the phase III Iressa Pan-ASia Study (IPASS). Lung Cancer. 2014; 83(2): 174–181.

76. Mok T.S., Wu Y.L., Thongprasert S.et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med. 2009; 361(10): 947–957.

77. Zhu C.Q., da Cunha Santos G., Ding K., Sakurada A.et al. Role of KRAS and EGFR as biomarkers of response to erlotinib in National Cancer Institute of Canada Clinical Trials Group Study BR.21. J Clin Oncol. 2008; 26(26): 4268–4275.

78. Han B., Tjulandin S., Hagiwara K.et al. Determining the prevalence of EGFR mutations in Asian and Russian patients (pts) with advanced non-small-cell lung cancer (aNSCLC) of adenocarcinoma (ADC) and non-ADC histology: Ignite Study. Ann Oncol. 2015; 26(suppl 1): 29–44.

79. Yang S.H., Mechanic L.E., Yang P.et al. Mutations in the tyrosine kinase domain of the epidermal growth factor receptor in non-small cell lung cancer. Clin Cancer Res. 2005; 11(6): 2106–2110.

80. Leidner R.S., Fu P., Clifford B.et al. Genetic abnormalities of the EGFR pathway in African American Patients with non-small-cell lung cancer. J Clin Oncol. 2009; 27(33): 5620–5626.

81. Riely G.J., Pao W., Pham D.et al. Clinical course of patients with non-small cell lung cancer and epidermal growth factor receptor exon 19 and exon 21 mutations treated with gefitinib or erlotinib. Clin Cancer Res. 2006; 12(3 pt 1): 839–844.

82. Cote M.L., Haddad R., Edwards D.J.et al. Frequency and type of epidermal growth factor receptor mutations in African Americans with non-small cell lung cancer. J Thorac Oncol. 2011; 6(3): 627–630.

83. Reinersman J.M., Johnson M.L., Riely G.J.et al. Frequency of EGFR and KRAS mutations in lung adenocarcinomas in African Americans. J Thorac Oncol. 2011; 6(1): 28–31.

84. Arrieta O., Cardona A.F., Federico Bramuglia G.et al. Genotyping non-small cell lung cancer (NSCLC) in Latin America. J Thorac Oncol. 2011; 6(11): 1955–1959.

85. Corrales-Rodriguez L., Abbas J., Ramos-Esquivel A.et al. Immunohistochemistry as a predictor of EGFR mutations: a retrospective case-control study. J Thorac Oncol. 2014; 9(9 suppl 3): S176.

86. Rojas Vigott R., Ugalde Gamboa L., Rojas Solano J. Thoracic oncology clinic: our first 200 cases. San José, Costa Rica. J Thorac Oncol. 2014; 9(9 suppl 3): S182.

87. Castillo-Fernandez O., Arauz E., Cabreja A.et al. EGFR mutation and outcomes in patients with metastatic NSCLC treated with erlotinib at Instituto Oncologico Nacional, Panama. J Thorac Oncol. 2014; 9(9 suppl 3): S189.

88. Riely G.J., Marks J., Pao W. KRAS mutations in non-small cell lung cancer. Proc Am Thorac Soc. 2009; 6(2): 201–205.

89. Adjei A.A. Blocking oncogenic Ras signaling for cancer therapy. J Natl Cancer Inst. 2001; 93(14): 1062–1074.

90. Cox A.D., Der C.J. Ras history: the saga continues. Small GTPases. 2010; 1(1): 2–27.

91. Castellano E., Santos E. Functional specificity of ras isoforms: so similar but so different. Genes Cancer. 2011; 2(3): 216–231.

92. Pao W., Girard N. New driver mutations in non-small-cell lung cancer. Lancet Oncol. 2011; 12(2): 175–180.

93. Ding L., Getz G., Wheeler D.A.et al. Somatic mutations affect key pathways in lung adenocarcinoma. Nature. 2008; 455(7216): 1069–1075.

94. Califano R., Landi L., Cappuzzo F. Prognostic and predictive value of K-RAS mutations in non-small cell lung cancer. Drugs. 2012; 72(suppl 1): 28–36.

95. Meng D., Yuan M., Li X.et al. Prognostic value of K-RAS mutations in patients with non-small cell lung cancer: a systematic review with metaanalysis. Lung Cancer. 2013; 81(1): 1–10.

96. Riely G.J., Kris M.G., Rosenbaum D.et al. Frequency and distinctive spectrum of KRAS mutations in never smokers with lung adenocarcinoma. Clin Cancer Res. 2008; 14(18): 5731–5734.

97. Sun Y., Ren Y., Fang Z.et al. Lung adenocarcinoma from East Asian never-smokers is a disease largely defined by targetable oncogenic mutant kinases. J Clin Oncol. 2010; 28(30): 4616–4620.

98. El-Telbany A., Ma P.C. Cancer genes in lung cancer: racial disparities: are there any? Genes Cancer. 2012; 3(7-8): 467–480.

99. Bauml J., Mick R., Zhang Y.et al. Frequency of EGFR and KRAS mutations in patients with non small cell lung cancer by racial background: do disparities exist? Lung Cancer. 2013; 81(3): 347–353.

100. McQuitty E., Zhang W., Hendrickson H.et al. Lung adenocarcinoma biomarker incidence in Hispanic versus non-Hispanic white patients. Arch Pathol Lab Med. 2014; 138(3): 390–394.

101. Shaw R.J., Kosmatka M., Bardeesy N.et al. The tumor suppressor LKB1 kinase directly activates AMP-activated kinase and regulates apoptosis in response to energy stress. Proc Natl Acad Sci U S A. 2004; 101(10): 3329–3335.

102. Cao Y., Li H., Liu H.et al. The serine/threonine kinase LKB1 controls thymocyte survival through regulation of AMPK activation and Bcl-XL expression. Cell Res. 2010; 20(1): 99–108.

103. Gao Y., Ge G., Ji H. LKB1 in lung cancerigenesis: a serine/threonine kinase as tumor suppressor. Protein Cell. 2011; 2(2): 99–107.

104. Hemminki A., Markie D., Tomlinson I.et al. A serine/threonine kinase gene defective in Peutz-Jeghers syndrome. Nature. 1998; 391(6663): 184–187.

105. Lim W., Hearle N., Shah B.et al. Further observations on LKB1/STK11 status and cancer risk in Peutz-Jeghers syndrome. Br J Cancer. 2003; 89(2): 308–313.

106. Sanchez-Cespedes M., Parrella P., Esteller M.et al. Inactivation of LKB1/STK11 is a common event in adenocarcinomas of the lung. Cancer Res. 2002; 62(13): 3659–3662.

107. Shah U., Sharpless N.E., Hayes D.N. LKB1 and lung cancer: more than the usual suspects. Cancer Res. 2008; 68(10): 3562–3565.

108. Sanchez-Cespedes M. The role of LKB1 in lung cancer. Fam Cancer. 2011; 10(3): 447–453.

109. Matsumoto S., Iwakawa R., Takahashi K.et al. Prevalence and specificity of LKB1 genetic alterations in lung cancers. Oncogene. 2007; 26(40): 5911–5918.

110. Ji H., Ramsey M.R., Hayes D.N.et al. LKB1 modulates lung cancer differentiation and metastasis. Nature. 2007; 448(7155): 807–810.

111. O'Neill G.M., Seo S., Serebriiskii I.G.et al. A new central scaffold for metastasis: parsing HEF1/Cas-L/NEDD9. Cancer Res. 2007; 67(19): 8975–8979.

112. Gao Y., Xiao Q., Ma H.et al. LKB1 inhibits lung cancer progression through lysyl oxidase and extracellular matrix remodeling. Proc Natl Acad Sci U S A. 2010; 107(44): 18892–18897.

113. Wingo S.N., Gallardo T.D., Akbay E.A.et al. Somatic LKB1 mutations promote cervical cancer progression. PloS One. 2009; 4(4): e5137.

114. Sanchez-Cespedes M. A role for LKB1 gene in human cancer beyond the Peutz-Jeghers syndrome. Oncogene. 2007; 26(57): 7825–7832.

115. Koivunen J.P., Kim J., Lee J.et al. Mutations in the LKB1 tumour suppressor are frequently detected in tumours from Caucasian but not Asian lung cancer patients. Br J Cancer. 2008; 99(2): 245–252.

116. Onozato R., Kosaka T., Achiwa H.et al. LKB1 gene mutations in Japanese lung cancer patients. Cancer Sci. 2007; 98(11): 1747–1751.

117. Gao B., Sun Y., Zhang J.et al. Spectrum of LKB1, EGFR, and KRAS mutations in Chinese lung adenocarcinomas. J Thorac Oncol. 2010 Aug;5(8): 1130–1135.

118. Sun Y.H., Ren Y., Fang Z.Y.et al. Lung adenocarcinoma from East Asian never-smokers is a disease largely defined by targetable oncogenic mutant kinases. J Clin Oncol. 2010; 28(30): 4616–4620.

119. Schabath M.B., Welsh E.A., Fulp W.J.et al. Differential association of STK11 and TP53 with KRAS mutation-associated gene expression, proliferation and immune surveillance in lung adenocarcinoma. Oncogene. 2016; 35(24): 3209–3216.

120. Forcet C., Etienne-Manneville S., Gaude H.et al. Functional analysis of Peutz-Jeghers mutations reveals that the LKB1 C-terminal region exerts a crucial role in regulating both the AMPK pathway and the cell polarity. Hum Mol Genet. 2005; 14(10): 1283–1292.

121. Sánchez-Torres J.M., Viteri S., Molina M.A.et al. BRAF mutant non-small cell lung cancer and treatment with BRAF inhibitors. Transl Lung Cancer Res. 2013; 2(3): 244–250.

122. Davies H., Bignell G.R., Cox C.et al. Mutations of the BRAF gene in human cancer. Nature. 2002; 417(6892): 949–954.

123. Naoki K., Chen T.H., Richards W.G.et al. Missense mutations of the BRAF gene in human lung adenocarcinoma. Cancer Res. 2002; 62(23): 7001–7003.

124. Brose M.S., Volpe P., Feldman M.et al. BRAF and RAS mutations in human lung cancer and melanoma. Cancer Res. 2002; 62(23): 6997–7000.

125. Marchetti A., Felicioni L., Malatesta S.et al. Clinical features and outcome of patients with non-small-cell lung cancer harboring BRAF mutations. J Clin Oncol. 2011; 29(26): 3574–3579.

126. Samuels Y., Wang Z., Bardelli A.et al. High frequency of mutations of the PIK3CA gene in human cancers. Science. 2004; 304(5670): 554.

127. Kawano O., Sasaki H., Endo K.et al. PIK3CA mutation status in Japanese lung cancer patients. Lung Cancer. 2006; 54(2): 209–215.

128. Soda M., Choi Y.L., Enomoto M.et al. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature. 2007; 448(7153): 561–566.

129. Koivunen J.P., Mermel C., Zejnullahu K.et al. EML4-ALK fusion gene and efficacy of an ALK kinase inhibitor in lung cancer. Clin Cancer Res. 2008; 14(13): 4275–4283.

130. Wong D.W., Leung E.L., So K.K.et al. The EML4-ALK fusion gene is involved in various histologic types of lung cancers from nonsmokers with wild-type EGFR and KRAS. Cancer. 2009; 115(8): 1723–1733.

131. Inamura K., Takeuchi K., Togashi Y.et al. EML4-ALK fusion is linked to histological characteristics in a subset of lung cancers. J Thorac Oncol. 2008; 3(1): 13–17.

132. Inamura K., Takeuchi K., Togashi Y.et al. EML4-ALK lung cancers are characterized by rare other mutations, a TTF-1 cell lineage, an acinar histology, and young onset. Mod Pathol. 2009; 22(4): 508–515.

133. Ren S., Kuang P., Zheng L.et al. Analysis of driver mutations in female non-smoker Asian patients with pulmonary adenocarcinoma. Cell Biochem Biophys. 2012; 64(2): 155–160.

134. Li C., Fang R., Sun Y.et al. Spectrum of oncogenic driver mutations in lung adenocarcinomas from East Asian never smokers. PLoS One. 2011; 6(11): e28204.

135. Kim H.R., Shim H.S., Chung J.H.et al. Distinct clinical features and outcomes in never-smokers with non-small cell lung cancer who harbor EGFR or KRAS mutations or ALK rearrangement. Cancer. 2012; 118(3): 729–739.

136. Shinmura K., Kageyama S., Tao H.et al. EML4-ALK fusion transcripts, but no NPM-, TPM3-, CLTC-, ATIC-, or TFG-ALK fusion transcripts, in non-small cell lung carcinomas. Lung Cancer. 2008; 61(2): 163–169.

137. Martelli M.P., Sozzi G., Hernandez L.et al. EML4-ALK rearrangement in non-small cell lung cancer and non-tumor lung tissues. Am J Pathol. 2009; 174(2): 661–670.

Cite article

Cite article

OR

If you have citation software installed, you can download article citation data to the citation manager of your choice

Information, rights and permissions

Information

Published In

Volume 23, Issue 4

Pages: 338 - 346

Article first published online: October 1, 2016

Issue published: October 2016

Rights and permissions

© 2016 SAGE Publications.

Request permissions for this article.

Request Permissions

PubMed: 27842323

Authors

Affiliations

Matthew B. Schabath, Phd

Departments of Cancer Epidemiology, H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida

[email protected]

View all articles by this author

W. Douglas Cress, Phd

Molecular Oncology, H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida

View all articles by this author

Teresita Muñoz-Antonia, Phd

Tumor Biology Program, H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida.

View all articles by this author

Notes

Department of Cancer Epidemiology, Moffitt Cancer Center, 12902 Magnolia Drive, MRC-CANCON T, Tampa, FL 33612. E-mail: [email protected]

No significant relationships exist between the authors and the companies/organizations whose products or services may be referenced in this article.

Metrics and citations

Metrics

This article was published in Cancer Control.

VIEW ALL JOURNAL METRICS

Total views and downloads: 1450

^*Article usage tracking started in December 2016

See the impact this article is making through the number of times it’s been read, and the Altmetric Score.
Learn more about the Altmetric Scores

Receive email alerts when this article is cited

SIGN UP TO CITATION ALERTS

Web of Science: 71 view articles Opens in new tab

Crossref: 70

Cytokine Signatures for Lung Cancer Diagnosis in African American Popu...
Go to citation Crossref Google Scholar
Envonalkib versus crizotinib for treatment-naive ALK-positive non-smal...
Go to citation Crossref Google Scholar
Lung cancer survival and sex-specific patterns in Portugal: A populati...
Go to citation Crossref Google Scholar
Do Current Lung Cancer Clinical Trials Represent All Patient Populatio...
Go to citation Crossref Google Scholar
Racial, ethnic and gender trends in lung cancer mortality rates in the...
Go to citation Crossref Google Scholar
Disparities Across the Continuum of Lung Cancer Care
Go to citation Crossref Google Scholar
Simultaneous Denoising and Heterogeneity Learning for Time Series Data
Go to citation Crossref Google Scholar
Characterizing Lung Cancer Burden Among Asian-American Communities in ...
Go to citation Crossref Google Scholar
Smoking Behaviors Among Black and Hispanic Cancer Patients: A Systemat...
Go to citation Crossref Google Scholar
Diesel Exhaust Exposure and Cause-Specific Mortality in the Diesel Exh...
Go to citation Crossref Google Scholar
Sex Differences in Lung Cancer
Go to citation Crossref Google Scholar
Ethnic, racial and migrant inequalities in respiratory health
Go to citation Crossref Google Scholar
Uptake of invitations to a lung health check offering low-dose CT lung...
Go to citation Crossref Google Scholar
Precision Medicine Approaches for Stratification and Development of No...
Go to citation Crossref Google Scholar
Clinical Profile, Practice Pattern, and Outcomes With First-Line Thera...
Go to citation Crossref Google Scholar
Potential therapeutic molecular targets for better outcomes for patien...
Go to citation Crossref Google Scholar
The Importance of the Immune System and Molecular Cell Signaling Pathw...
Go to citation Crossref Google Scholar
IMMUNOTHERAPY AS NOVEL TREATMENT OF LUNG CANCER: A SYSTEMATIC REVIEW
Go to citation Crossref Google Scholar
Show me the roads and give me a road map: Development of a patient con...
Go to citation Crossref Google Scholar
Racial difference in BMI and lung cancer diagnosis: analysis of the Na...
Go to citation Crossref Google Scholar
Medical mistrust among women with intersecting marginalized identities...
Go to citation Crossref Google Scholar
Lung Cancer in Women
Go to citation Crossref Google Scholar
Genomic landscape of lung adenocarcinomas in different races
Go to citation Crossref Google Scholar
Does race affect the long-term survival benefit of systemic therapy in...
Go to citation Crossref Google Scholar
Feasibility of an Antiracism Curriculum in an Academic Pulmonary, Crit...
Go to citation Crossref Google Scholar
Cross-ancestry genome-wide meta-analysis of 61,047 cases and 947,237 c...
Go to citation Crossref Google Scholar
Perspectives of Low-Income and Minority Populations With Lung Cancer: ...
Go to citation Crossref Google Scholar
The Applicability of the Results in the Asian Population of ORIENT-11 ...
Go to citation Crossref Google Scholar
The Beneficial Effects of Physical Activity in Lung Cancer Prevention ...
Go to citation Crossref Google Scholar
A prospective cohort study of physical activity in relation to lung ca...
Go to citation Crossref Google Scholar
Disease-Specific Health Disparities: A Targeted Review Focusing on Rac...
Go to citation Crossref Google Scholar
Eosinophilia and Lung Cancer: Analysis From Real-World Data and Mendel...
Go to citation Crossref Google Scholar
Prognostic significance of mean platelet volume in patients with lung ...
Go to citation Crossref Google Scholar Pub Med
Molecular Pathology of Lung Cancer
Go to citation Crossref Google Scholar
The Potential Role of Nutrition in Lung Cancer Establishment and Progr...
Go to citation Crossref Google Scholar
Calling Attention to the Role of Race-Driven Societal Determinants of ...
Go to citation Crossref Google Scholar
Disparities in Tumor Mutational Burden, Immunotherapy Use, and Outcome...
Go to citation Crossref Google Scholar
Comparative Effectiveness of Atezolizumab, Nivolumab, and Docetaxel in...
Go to citation Crossref Google Scholar
Safety of Surgery after Neoadjuvant Targeted Therapies in Non-Small Ce...
Go to citation Crossref Google Scholar
Assessment of Alectinib vs Ceritinib in ALK ...
Go to citation Crossref Google Scholar
Prognostic Molecular Indices of Resectable Hepatocellular Carcinoma: I...
Go to citation Crossref Google Scholar
Sarcopenia on preoperative chest computed tomography predicts cancer‐s...
Go to citation Crossref Google Scholar
Symptom Occurrence, Severity, and Self-Care Methods by Ethnicity and A...
Go to citation Crossref Google Scholar
Association between long-term exposure to high levels of ambient air p...
Go to citation Crossref Google Scholar
New USPSTF Guidelines for Lung Cancer Screening
Go to citation Crossref Google Scholar
Prevalence of Targetable Mutations in Black Patients With Lung Cancer:...
Go to citation Crossref Google Scholar
A reply to “Lung cancer outcomes: Are BMI and race clinically relevant...
Go to citation Crossref Google Scholar
Screening of latent TB infection in patients with recently diagnosed b...
Go to citation Crossref Google Scholar Pub Med
Management of lung cancer in Africa: Underdiagnosis and poor access to...
Go to citation Crossref Google Scholar
Validating a targeted next-generation sequencing assay and profiling s...
Go to citation Crossref Google Scholar
Patterns of cancer family history and genetic counseling eligibility a...
Go to citation Crossref Google Scholar
Validation of the 8th lung cancer TNM classification and clinical stag...
Go to citation Crossref Google Scholar
Mobile Lung Screening: Should We All Get on the Bus?
Go to citation Crossref Google Scholar
Catalog of Lung Cancer Gene Mutations Among Chinese Patients
Go to citation Crossref Google Scholar
Racial differences in characteristics and prognoses between Asian and ...
Go to citation Crossref Google Scholar
Evidence That Established Lung Cancer Mortality Disparities in America...
Go to citation Crossref Google Scholar
Pulmonary enteric adenocarcinoma: an overview
Go to citation Crossref Google Scholar
Model for predicting EGFR mutation status ...
Go to citation Crossref Google Scholar
Cross‑disease analysis identified novel common genes for both lung ade...
Go to citation Crossref Google Scholar
Clinical Outcomes Following Stereotactic Body Radiation Therapy (SBRT)...
Go to citation Crossref Google Scholar
Relationships Between Health Care Disparities and Coverage Policies fo...
Go to citation Crossref Google Scholar
Designing and Assessing Multilevel Interventions to Improve Minority H...
Go to citation Crossref Google Scholar
The LEAD study protocol: a mixed-method cohort study evaluating the lu...
Go to citation Crossref Google Scholar
Epidermal Growth Factor Receptor Gene in Non-Small-Cell Lung Cancer: T...
Go to citation Crossref Google Scholar
Survival analysis in Caucasian pulmonary adenocarcinoma patients based...
Go to citation Crossref Google Scholar
Histologic Lung Cancer Incidence Rates and Trends Vary by Race/Ethnici...
Go to citation Crossref Google Scholar
Keap1 Inhibits Metastatic Properties of NSCLC Cells by Stabilizing Arc...
Go to citation Crossref Google Scholar
Patient navigation for lung cancer screening among current smokers in ...
Go to citation Crossref Google Scholar
Somatic Mutations and Ancestry Markers in Hispanic Lung Cancer Patient...
Go to citation Crossref Google Scholar
Lung cancer mortality of residents living near petrochemical industria...
Go to citation Crossref Google Scholar

Figures and tables

Figures & Media

Tables

View Options

View options

PDF/ePub

Get access

If you have access to journal content via a personal subscription, university, library, employer or society, select from the options below:

Sage Journals profile

OR

Institution

Society

Alternatively, view purchase options below:

Purchase access

Purchase 24 hour online access to view and download content.

Read with DeepDyve